Understanding why some cancers spread faster than others remains a central puzzle for scientists. A team from the University of Geneva, working with the Ludwig Institute for Cancer Research, has uncovered a surprising twist: a common immune cell, the neutrophil, can be hijacked by tumors to actually help the disease grow.
When Defensive Cells Become Tumor Helpers
Neutrophils usually act as the body’s rapid responders, rushing to sites of infection or injury. In the context of cancer, however, they often signal a poorer prognosis. The new study shows that once neutrophils enter the tumor’s neighborhood, they start making a signaling protein called chemokine CCL3. Instead of rallying the immune system, CCL3 fuels the tumor’s expansion.
Decoding the Tumor’s Cellular Playground
“Tumors live in a densely populated cellular community, and teasing apart which interactions truly drive growth is a huge challenge,” explains Prof. Mikaël Pittet, the lead investigator. “Our previous work linked two macrophage genes to disease progression. Now we’ve identified a second variable—neutrophil‑derived CCL3—that appears across many cancer types.”
Re‑programming Neutrophils Without Disrupting Their Normal Role
To prove that CCL3 is the culprit, the researchers employed a suite of genetic tools that switched off the CCL3 gene only in neutrophils, leaving other cells untouched. When CCL3 was silenced, neutrophils still migrated into tumors but no longer boosted tumor growth, confirming that the chemokine, not the cells themselves, was the problem.
Big‑Data Confirmation
The team validated their lab findings by mining dozens of public cancer datasets. Advanced computational methods revealed a consistent pattern: high CCL3 levels in neutrophil‑rich tumors correlated with faster disease progression.
Why CCL3 Matters for Patients
Identifying CCL3 as a “tumor‑identity card” opens new possibilities for monitoring and treating cancer. If doctors can measure CCL3 activity, they may gain a clearer picture of how aggressive a tumor is and tailor therapies accordingly.
“We are gradually building a list of key variables that dictate a tumor’s fate,” says Pittet. “Each new marker brings us closer to truly personalized cancer care.”